Zymeworks Inc. shared a post on LinkedIn:
“Ongoing innovations in antibody-drug conjugates (ADCs) are revolutionizing cancer treatment.
Breakthroughs in linker-payload technologies and personalized medicine are enhancing therapeutic benefit and enabling treatments tailored to individual patients, providing new hope across various malignancies.
Explore how advancements in ADCs are redefining cancer treatment and our unique approach to their design and development in this article from Drug Target Review.”
Authors: Paul Moore, Raffaele Colombo and Jamie Rich
Source: Zymeworks Inc./LinkedIn